Trial Profile
A open-label,randomized controlled study of adjuvant therapy with TAP-144-SR (3M) in premenopausal breast cancer patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Leuprorelin (Primary) ; Tamoxifen
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Takeda
- 01 Jun 2016 New trial record